# Soleno Therapeutics Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Soleno Therapeutics Inc). ## Overview Soleno Therapeutics Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Its lead product is VYKAT XR (diazoxide choline) extended-release tablets, an oral treatment for hyperphagia in adults and children with Prader-Willi syndrome, with operations centered in the United States and potential expansion into other major markets. ## Products & services • VYKAT XR extended-release tablets • Rare-disease drug development • Commercialization of Prader-Willi syndrome therapy • Patient support and access programs through SOLENO ONE • U.S. specialty pharmacy distribution - **Commercial pharmaceutical product** (100%) — VYKAT XR prescription sales for hyperphagia in Prader-Willi syndrome. - **Drug development pipeline** (0%) — Research and regulatory work supporting future rare-disease therapeutics. - **Patient access and support services** (0%) — Education, financial assistance, and onboarding support via SOLENO ONE. - VYKAT XR extended-release tablets - Rare-disease drug development - Commercialization of Prader-Willi syndrome therapy - Patient support and access programs through SOLENO ONE - U.S. specialty pharmacy distribution ## Customers The company sells primarily to specialty pharmacy channels that dispense VYKAT XR pursuant to physician prescriptions. End users are patients with Prader-Willi syndrome, while prescribing decisions are made by physicians and treatment teams managing rare-disease care. Coverage and reimbursement decisions by payers are also important because they influence access and uptake. - **Specialty pharmacy channel** (primary) — Buys VYKAT XR and dispenses it to patients under prescription; critical for commercialization. - **Physicians and prescribers** (primary) — Recommend and prescribe VYKAT XR for eligible PWS patients based on clinical need. - **Patients with Prader-Willi syndrome** (primary) — Use the therapy to address hyperphagia and related disease burden. - **Payers and reimbursement decision-makers** (secondary) — Influence access through formulary placement, coverage, and patient out-of-pocket cost. - **Caregivers and patient advocates** (secondary) — Support treatment initiation, adherence, and navigation of access programs. - Specialty pharmacies that purchase and dispense VYKAT XR - Physicians treating Prader-Willi syndrome and hyperphagia - Patients with PWS and their caregivers - Healthcare payers that determine coverage and reimbursement - Rare-disease treatment centers and support networks ## Geography Soleno is headquartered in Redwood City, California and conducts its core commercial and operational activities in the United States. The company stores API and uses third-party manufacturers, logistics providers, and a specialty pharmacy network in the U.S., while also evaluating commercialization options for Europe, Japan, and other major markets. Geography matters because the business depends on U.S. regulatory approval and domestic supply-chain execution, with international expansion still subject to partner and market decisions. - Headquartered in Redwood City, California - Primary commercial market is the United States - API stored at third-party facilities in the U.S. - U.S. CMOs manufacture, package, and label VYKAT XR - Europe and Japan are potential future commercialization markets ## Strategy The company’s strategy is centered on building VYKAT XR into a commercial rare-disease product and expanding physician, payer, and patient adoption in the U.S. It is also building the sales, marketing, training, and support infrastructure needed for launch while evaluating whether to commercialize outside the U.S. directly or with partners. Capital access, manufacturing reliability, and reimbursement coverage are central to executing that plan. - **Commercialize VYKAT XR in the U.S.** (short-term) — The company’s value creation depends on physician adoption, patient access, and prescription growth. - **Build commercial infrastructure** (short-term) — A rare-disease launch requires targeted sales, medical affairs, and support capabilities. - **Expand internationally through partners or direct entry** (medium-term) — Ex-U.S. markets could broaden the addressable patient base while limiting execution risk through partnerships. - **Protect supply and manufacturing continuity** (short-term) — Commercial availability depends on third-party API, CMO, and logistics execution. - Expand U.S. commercialization of VYKAT XR - Build sales, marketing, training, and patient support capabilities - Secure payer coverage and reimbursement for access - Maintain reliable third-party manufacturing and supply - Evaluate ex-U.S. partnerships for Europe, Japan, and other markets ## Risks Soleno is highly dependent on the commercial success of a single approved product, which concentrates execution, reimbursement, and competitive risk. As a rare-disease pharmaceutical company, it also faces regulatory, manufacturing, intellectual property, and market-access risks that can materially affect adoption and supply continuity. International expansion, if pursued, adds partner, regulatory, and country-specific commercialization risk. - **Single-product dependence** [critical] — Revenue and enterprise value are tied to VYKAT XR adoption and durability. - **Market acceptance and reimbursement risk** [high] — Physicians, patients, caregivers, and payers must accept the therapy for commercial success. - **Manufacturing and supply-chain disruption** [high] — The company relies on third-party CMOs, 3PLs, and external API storage. - **Intellectual property and competitive pressure** [high] — Competing PWS therapies or broader appetite-suppression drugs could limit share. - **International regulatory and partner execution** [medium] — Ex-U.S. commercialization depends on later strategic decisions and local approvals. - Dependence on VYKAT XR as the sole approved product - Limited commercialization history and launch execution risk - Reimbursement and payer coverage may constrain uptake - Patent protection may not fully block competition - Third-party manufacturing and logistics create supply risk - Rare-disease pharma competition and regulatory risk ## Accounting Revenue is recognized for VYKAT XR upon delivery and transfer of title, but the transaction price includes estimates for rebates, discounts, returns, and copay assistance. That makes net product revenue sensitive to reserve assumptions, especially in an early commercialization period with limited sales history. The company also uses fair value estimates for contingent consideration, stock-based compensation, and financial instruments, which can materially affect reported earnings. - **Revenue reserves under ASC 606** — Can materially change product revenue and gross-to-net deductions - **Contingent consideration fair value** — Can create volatility in operating expenses and net income - **Stock-based compensation** — Affects SG&A and R&D expense trends - **Fair value of marketable securities and financial instruments** — Can affect other income/expense and balance sheet values - Net product revenue depends on reserve estimates for rebates and returns - Revenue timing is point-in-time when title transfers to the customer - Contingent consideration is marked to fair value based on sales milestones - Stock-based compensation affects operating expense and earnings - Marketable securities and financial instruments require valuation estimates --- *Last updated: 2026-04-29T04:55:47.800471+00:00*